November 2026
Policy proposals to restrict U.S. biopharmaceutical investment involving China could have major unintended consequences for American innovation and economic competitiveness.
November 2026
Policy proposals to restrict U.S. biopharmaceutical investment involving China could have major unintended consequences for American innovation and economic competitiveness.